comprehensive -WSS

comprehensive

author：focus 2025-09-07 21:54:53 - browse：29357

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Change Healthcare: What is it, why does its cyberattack matter?

WSS

STAT Report: Patient voices and perspectives

Readout Newsletter: BridgeBio, Akero, and human embryo models

Florida health officials providing scant details on measles cases

Fetal cell organoids grown from amniotic fluid, study finds

How doctors’ personal politics affect patients

What causes rare myocarditis in young men after Covid vaccines?

leisure time

comprehensive

leisure time

In Memoriam: Notable people who died in 2023

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Psychedelics group wrestles with new pharma identity

Dems pitch expanding Medicare power to negotiate drug prices

Moonlake's readout produced a cash windfall. Risks remain

Former reverend arrested for allegedly killing 8

Cancer drug shortages should be causing more outrage

Why patients can’t get everything they want on drug pricing

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Truvian presents data for its desktop blood

focus

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Families look for replacement for GSK asthma drug Flovent

New lawsuit accuses health insurer Cigna of denying claims in bulk

Fetal cell organoids grown from amniotic fluid, study finds

Democrats decry new health bill for going easy on private equity

Longer MASH drug regimen improved liver, Akero study finds

entertainment

leisure time

hotspot

leisure time